Médecins pour Médulloblastome à l'étranger — Page 2

Le Dr Yildiz a beaucoup publié sur les tumeurs neuroendocrines et les cancers rares, ses travaux de recherche ayant été présentés dans des revues médicales internationales.

• Se spécialiser dans les tumeurs neuroendocrines et les cas de cancers rares
• Publier plus de 17 articles évalués par des pairs en oncologie
• Travailler à l'hôpital universitaire Medipol Mega
• Être expérimenté dans le diagnostic et le traitement de cas oncologiques complexes

Le professeur Shlomi Constantini est un expert en neurochirurgie pédiatrique, spécialisé dans les tumeurs du cerveau et de la moelle épinière au centre médical Sourasky.

• Plus de 15 ans d'expérience en neurochirurgie
• Formé à la microneurochirurgie et à la neuro-endoscopie avancée
• Lauréat du prix Mahaly de la meilleure recherche clinique de l'AANS
• Spécialisé dans les interventions microchirurgicales et reconstructives
• Membre de plusieurs sociétés neurochirurgicales internationales

Le Dr Dror Levin est spécialisé dans les cancers pédiatriques et coordonne le traitement des sarcomes au centre médical Sourasky – le principal établissement d'Israël.

• Directeur de l'oncologie hématologique pédiatrique à Sourasky
• Formé à l'Institut orthopédique Rizzoli – un leader mondial du cancer des os
• Membre de l'ISPHO (Société israélienne d'hématologie et d'oncologie pédiatriques)
• Se spécialiser dans les troubles sanguins et les problèmes de coagulation chez les enfants

Le professeur Wolfgang Köstler est un expert de premier plan en thérapies ciblées contre le cancer, avec plus de deux décennies d'expérience en oncologie médicale.

• Se spécialiser dans le cancer du sein et les tumeurs gynécologiques malignes
• Professeur associé à l'Université de médecine de Vienne
• Chef adjoint de la division clinique d'oncologie
• Se concentrer sur la thérapie anticancéreuse systémique individualisée et l'immunothérapie

Le professeur Keil est spécialisé dans les techniques d'imagerie avancées pour les cas complexes, y compris le médulloblastome, à l'Hôpital Académique de Solingen.

• Diplômé avec mention de l'Université Julius-Maximilian de Wurtzbourg
• Expert en IRM, scanner et échographie pour un diagnostic précis
• Médecin-chef de radiologie diagnostique et interventionnelle depuis 2022
• Formé auprès du célèbre professeur Rolf W. Günther à Aix-la-Chapelle

Le Dr Inta Jaunalksne se spécialise en virothérapie – une approche de pointe en immunologie avec plus de 30 ans d'expérience.

• Chef du centre d'immunologie clinique de l'hôpital universitaire clinique Pauls Stradins
• Diplômée de l'Institut médical de Riga avec un internat en médecine interne
• Se concentrer sur les traitements immunologiques innovants

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Le professeur Deniz Konya est spécialisé dans les tumeurs de la colonne vertébrale à l'hôpital Medical Park Göztepe, avec plus de 15 ans d'expérience en neurochirurgie.

• Formé au Brigham and Women's Hospital de la Harvard Medical School
• Membre du conseil d'administration de la Société Turque de la Colonne Vertébrale et de groupes internationaux spécialisés
• Auteur de 47 articles évalués par des pairs sur les traitements rachidiens
• Réaliser des interventions avancées pour les fractures et déformations de la colonne vertébrale

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Spécialisé dans le médulloblastome avec une formation approfondie en oncologie médicale à l'université d'Akdeniz.

• Certifié en oncologie médicale depuis 2018
• Plus de 15 ans d'expérience en oncologie
• Travaille au complexe hospitalier Medical Park Antalya

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Le professeur associé Nail Paksoy apporte une expertise spécialisée dans le médulloblastome, issue de son clinicat à l'Institut d'oncologie de l'Université d'Istanbul et de son rôle actuel à l'hôpital Medipol Bahçelievler.

• Certifié par l'ESMO en oncologie médicale
• Participation à 8 essais cliniques internationaux pour les cancers avancés
• Publication de plusieurs études évaluées par des pairs sur les traitements des cancers rares
• Réalisation d'une double formation de spécialisation en oncologie médicale et en allergologie-immunologie

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.